CU20210101A7 - Polipéptidos que se unen a factores de crecimiento proangiogénicos - Google Patents
Polipéptidos que se unen a factores de crecimiento proangiogénicosInfo
- Publication number
- CU20210101A7 CU20210101A7 CU2021000101A CU20210101A CU20210101A7 CU 20210101 A7 CU20210101 A7 CU 20210101A7 CU 2021000101 A CU2021000101 A CU 2021000101A CU 20210101 A CU20210101 A CU 20210101A CU 20210101 A7 CU20210101 A7 CU 20210101A7
- Authority
- CU
- Cuba
- Prior art keywords
- polypeptides
- growth factors
- bind
- proangiogenic growth
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>Polipéptidos que se unen a factores de crecimiento proangiogénicos que comprende en su secuencia aminoacídica al menos un fragmento de anticuerpo de simple dominio (V<sub>H</sub>H) y vector que codifica para el polipéptido que se une a factores de crecimiento proangiogénicos. Composición farmacéutica que comprende dichos polipéptidos o dicho vector que codifica para los polipéptidos que se unen a factores de crecimiento proangiogénicos. Uso de los polipéptidos que se unen a factores de crecimiento proangiogénicos, o del vector que codifica para dichos polipéptidos, para la manufactura de un medicamento. La invención también contempla un método de tratamiento de una patología que cursa con el incremento de la angiogénesis, la inflamación o la inmunosupresión, en un individuo que lo necesita, donde se administra una cantidad terapéuticamente efectiva de una composición farmacéutica que comprende el polipéptido que se une a factores de crecimiento proangiogénicos o el vector que codifica para dicho polipéptido.</p>
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2021000101A CU24770B1 (es) | 2021-12-15 | 2021-12-15 | Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos |
| AU2022414936A AU2022414936A1 (en) | 2021-12-15 | 2022-10-06 | Polypeptides that bind proangiogenic growth factors |
| US18/720,961 US20250326826A1 (en) | 2021-12-15 | 2022-10-06 | Polypeptides that bind proangiogenic growth factors |
| EP22797265.0A EP4450519A1 (en) | 2021-12-15 | 2022-10-06 | Proangiogenic growth factor-binding polypeptides |
| JP2024536293A JP2025500928A (ja) | 2021-12-15 | 2022-10-06 | 血管新生促進増殖因子結合ポリペプチド |
| MX2024007506A MX2024007506A (es) | 2021-12-15 | 2022-10-06 | Polipeptidos que se unen a factores de crecimiento proangiogenicos. |
| CA3241181A CA3241181A1 (en) | 2021-12-15 | 2022-10-06 | Polypeptides that bind proangiogenic growth factors |
| PCT/CU2022/050011 WO2023109982A1 (es) | 2021-12-15 | 2022-10-06 | Polipéptidos que se unen a factores de crecimiento proangiogénicos |
| CN202280091479.7A CN119013291A (zh) | 2021-12-15 | 2022-10-06 | 结合促血管发生生长因子的多肽 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2021000101A CU24770B1 (es) | 2021-12-15 | 2021-12-15 | Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20210101A7 true CU20210101A7 (es) | 2023-07-12 |
| CU24770B1 CU24770B1 (es) | 2025-09-01 |
Family
ID=84043977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2021000101A CU24770B1 (es) | 2021-12-15 | 2021-12-15 | Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250326826A1 (es) |
| EP (1) | EP4450519A1 (es) |
| JP (1) | JP2025500928A (es) |
| CN (1) | CN119013291A (es) |
| AU (1) | AU2022414936A1 (es) |
| CA (1) | CA3241181A1 (es) |
| CU (1) | CU24770B1 (es) |
| MX (1) | MX2024007506A (es) |
| WO (1) | WO2023109982A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| CU23636A1 (es) | 2006-11-01 | 2011-03-21 | Ct Ingenieria Genetica Biotech | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) |
| CU23895B1 (es) | 2010-12-28 | 2013-05-31 | Biorec Sa | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| WO2013134414A1 (en) * | 2012-03-06 | 2013-09-12 | Galaxy Biotech, Llc | Bispecific antibodies with an fgf2 binding domain |
| PE20181363A1 (es) * | 2015-09-23 | 2018-08-27 | Genentech Inc | Variantes optimizadas de anticuerpos anti-vegf |
-
2021
- 2021-12-15 CU CU2021000101A patent/CU24770B1/es unknown
-
2022
- 2022-10-06 CN CN202280091479.7A patent/CN119013291A/zh active Pending
- 2022-10-06 MX MX2024007506A patent/MX2024007506A/es unknown
- 2022-10-06 CA CA3241181A patent/CA3241181A1/en active Pending
- 2022-10-06 JP JP2024536293A patent/JP2025500928A/ja active Pending
- 2022-10-06 US US18/720,961 patent/US20250326826A1/en active Pending
- 2022-10-06 WO PCT/CU2022/050011 patent/WO2023109982A1/es not_active Ceased
- 2022-10-06 EP EP22797265.0A patent/EP4450519A1/en active Pending
- 2022-10-06 AU AU2022414936A patent/AU2022414936A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024007506A (es) | 2024-09-10 |
| CN119013291A (zh) | 2024-11-22 |
| WO2023109982A1 (es) | 2023-06-22 |
| CA3241181A1 (en) | 2023-06-22 |
| US20250326826A1 (en) | 2025-10-23 |
| AU2022414936A1 (en) | 2024-07-11 |
| CU24770B1 (es) | 2025-09-01 |
| JP2025500928A (ja) | 2025-01-15 |
| EP4450519A1 (en) | 2024-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025003540A1 (es) | Anticuerpo monoclonal anti-hccr8; composición farmacéutica, y su uso para el tratamiento del cáncer. | |
| PE20240631A1 (es) | Composiciones de inhibidores peptidicos del receptor de interleucina-23 | |
| PE20240639A1 (es) | Moduladores de la proteolisis bcl6 y metodos de uso asociados | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| CO6180451A2 (es) | Polipeptidos heterodimericos il -17 a/f y usos terapeuticos de los mismos | |
| IL277215B1 (en) | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis | |
| PE20211417A1 (es) | Analogos novedosos de glp-1 | |
| PE20221263A1 (es) | Agentes de union a ilt3 y metodos de uso de los mismos | |
| PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| PE20221326A1 (es) | Anticuerpos anti-mertk y metodos de uso de los mismos | |
| CO2020013221A2 (es) | Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos | |
| MX2023008115A (es) | Terapia con receptores quiméricos. | |
| CO2020012621A2 (es) | Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso | |
| ECSP20020949A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos | |
| RU2017146220A (ru) | Конъюгированные через cys80 иммуноглобулины | |
| AR123671A1 (es) | Anticuerpo fn14 anti-humano | |
| CO2025004790A2 (es) | Anticuerpo anti-il-1r3 humanizado y métodos de uso | |
| CU20210101A7 (es) | Polipéptidos que se unen a factores de crecimiento proangiogénicos | |
| AR121441A1 (es) | Anticuerpos anti-axl y composiciones | |
| PE20251275A1 (es) | Agentes aglutinantes 5t4 y usos de los mismos | |
| MX2022001278A (es) | Materiales y métodos para el direccionamiento al receptor de anticuerpos poliméricos. | |
| MX2024011128A (es) | Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico. | |
| CL2025001595A1 (es) | Agonistas triples de los receptores de glp1/gip/npy2 | |
| MX2023011929A (es) | Anticuerpos anti-c-met y conjugados de anticuerpo-farmaco. |